IFN-αR Inhibitors
Interferons (IFNs) are a group of proteins known for their ability to interfere with viral replication within host cells. Specifically, Interferon-alpha (IFN-α) is a type of interferon that plays a key role in the body's immune response to viral infections. IFN-α achieves this through its interaction with specific receptors on the cell surface, notably the IFN-α receptor (IFN-αR). Once activated, this receptor initiates a cascade of intracellular signaling pathways that result in a variety of cellular responses, including enhanced antiviral defenses.
IFN-αR inhibitors are molecules designed to specifically target and inhibit the activity of the IFN-α receptor. By doing so, they block the receptor's ability to recognize and respond to IFN-α, thereby interrupting the downstream signaling events it typically mediates. This inhibition is achieved through various chemical mechanisms, depending on the specific inhibitor in question. Some inhibitors may bind directly to the receptor's ligand-binding domain, preventing IFN-α from interacting with it. Others may interact with different regions of the receptor or its associated proteins, thereby altering its structural conformation and hampering its function. The exact mechanism of action, as well as the specificity and affinity of these inhibitors for the IFN-αR, can vary significantly between different molecules. The discovery and characterization of these inhibitors has deepened our understanding of the intricate molecular interactions underpinning the body's immune responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor, targeting JAK1 and JAK2. IFN-αR signaling works through the JAK-STAT pathway. By inhibiting JAK1 and JAK2, Ruxolitinib can prevent the downstream signaling initiated by IFN-αR activation. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Another JAK inhibitor, Baricitinib specifically targets JAK1 and JAK2. Like Ruxolitinib, it can prevent the downstream signaling of IFN-αR by inhibiting these JAK kinases. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
tyrosine kinase inhibitor. They can suppress IFN-α signaling, possibly by affecting the receptor itself or the downstream signaling molecules. Their broad kinase inhibition profile means they can impact multiple pathways, including the JAK-STAT pathway downstream of IFN-αR. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
tyrosine kinase inhibitor. They can suppress IFN-α signaling, possibly by affecting the receptor itself or the downstream signaling molecules. Their broad kinase inhibition profile means they can impact multiple pathways, including the JAK-STAT pathway downstream of IFN-αR. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
An immunomodulatory drug, Leflunomide can inhibit the enzyme dihydroorotate dehydrogenase (DHODH), impacting pyrimidine synthesis. This can reduce the production of IFN-α, which in turn can affect the activation of IFN-αR. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Originally an antimalarial drug, Hydroxychloroquine can affect endosomal pH and disrupt the endosomal signaling of toll-like receptors (TLRs). This can lead to a reduction in IFN-α production, thereby affecting IFN-αR signaling. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
An immunosuppressant, Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), affecting guanosine synthesis. This can lead to decreased IFN-α production, potentially affecting IFN-αR signaling. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
A corticosteroid, Dexamethasone can suppress various immune responses. Its broad anti-inflammatory effects can lead to a reduction in IFN-α production and, consequently, reduced IFN-αR signaling. | ||||||